Being patient: what delays access to new drugs in Europe?
On average, the first citizen to access a new drug in Belgium will wait 13 months longer for it than someone prescribed the same drug in Germany or the UK, despite an EU-wide licensing process. This suggests that country-specific drug regulation—the ‘fourth hurdle’ faced by drug manufacturers—may go a long way to explaining launch delay across Europe.
Related
Podcasts
Bridging the water investment gap: how can investment be secured?
This latest episode of Top of the Agenda, recorded in front of a live audience at Oxera’s new London office, explores how the investment needed to meet global commitments to safe water and sanitation can be encouraged and secured. The United Nations’ Sustainable Development Goal 6 (SDG 6)… Read More
Oxera responds to Ofgem’s call for input on AI assurance
We welcome Ofgem’s recent call for input on AI assurance. The transition to a net-zero, highly dynamic energy sector relies on the successful integration of AI, and we support the development of a framework that addresses the unique economics, innovation drivers and risks of the… Read More